Johnson & Johnson reported strong pharmaceutical growth with Innovative Medicine up 7.9%, driving optimism for its stock with a 12-month price target of $288.66, an 11.48% upside. However, its MedTech segment showed weak international sales growth and operational challenges, which could pressure earnings and stock performance. The company faces $7 billion in charges from legal settlements and partnerships, but promising drug launches like Tremfya and CAPLYTA support a bullish outlook. Investors will watch if MedTech can improve to justify JNJ's premium valuation over rivals Merck and AbbVie.
Johnson & Johnson's mixed business performance adds context to its current trading on Pluang, where JNJ shares are priced at USD 260.70, up 1.13% as of Oct 22, 2026 20:11 WIB. The stock holds a strong market cap of $621.22 billion and a dividend yield of 2.08%, with 90% of Pluang orders on the buy side. Comparatively, Merck trades at USD 151.45 and AbbVie at USD 277.45, showing different investor sentiment in the health sector.
Johnson & Johnson has increased its dividend annually for 64 years, yet its stock returns over the past decade were outpaced by the S&P 500 index. While a $1,000 investment in J&J grew to about $2,957 with dividends reinvested, the S&P 500 grew even ...
Johnson & Johnson reported a 96% drop in GAAP net earnings for Q3 due to a one-time legal charge related to talc litigation, but adjusted earnings fell only 7.5%. The company raised its full-year adjusted EPS guidance and maintained a strong dividend...
With 10-year Treasury yields near 5%, three Dividend Kings—Johnson & Johnson, Procter & Gamble, and Altria—stand out by raising dividends for over 50 consecutive years while maintaining low market volatility (low beta). These companies generate stron...
Johnson & Johnson announced that TREMFYA (guselkumab) maintained or improved fistula remission in adults with Crohn's disease through 48 weeks in the Phase 3 FUZION study. The combined fistula remission rate increased from 28% at Week 24 to 35% at We...
Johnson & Johnson reported a solid quarter with 6% sales growth and strong oncology business expansion, despite a slight miss in MedTech. Analysts maintain a bullish outlook with a 12-month price target of $291.60, implying a 15.6% upside from curren...
